Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) has been nothing short of a nightmare for investors since last summer, having lost an eye-popping $90 billion in market value. The stock closed at a meekly $31 a share on Thursday. It had touched a peak value of $263.8 in August. It makes us wonder about what Valeant could have done to prevent the crash.
